Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Names Brian Goff to its Board of Directors

Read More

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Read More


More events are coming soon.


OUR COMMITMENT Intellia’s objective is to build a sustainable company delivering on our commitment to the patients we serve, our employees, community, environment and shareholders.

We believe Environmental, Social and Governance (ESG) principles support long term value creation. Throughout this report, we have highlighted our approach to managing risk and taking advantage of opportunities in key ESG areas the areas that are most relevant to the long term sustainability of our company.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.